Future Health Pharma GmbH has announced on behalf of the manufacturer Novavax that it will not be pursuing the change of marketing authorisation for its COVID-19 vaccine adapted against Omicron sub-variant XBB.1.5. The pharmaceutical company has withdrawn the application for authorisation of the protein-based vaccine Nuvaxovid submitted to Swissmedic on 30 August 2023.
No new applications for authorisation of COVID-19 vaccines against the XBB.1.5 variant are therefore currently pending in Switzerland. The Comirnaty XBB.1.5 vaccine from Pfizer and the Spikevax XBB.1.5 vaccine from Moderna Switzerland GmbH have already been approved.